HUTCHMED highlights clinical data to be presented at ESMO Congress 2024 and World Conference on Lung Cancer 2024

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 9, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the World Conference on Lung Cancer 2024 (“WCLC24”) in San Diego, USA, and the European Society for Medical Oncology (“ESMO”) Congress 2024, taking place in Barcelona, ​​Spain.

Results from the FLOWERS trial, a prospective, two-arm, randomized, multicenter phase II clinical trial of osimertinib with or without savolitinib as first-line treatment in EGFRm, MET-aberrant advanced non-small cell lung cancer (“NSCLC”) patients, are being presented at WCLC24. As of May 28, 2024, median follow-up was 8.2 months. Patients treated with osimertinib plus savolitinib (Cohort 2, N=21) demonstrated deeper and more durable responses than osimertinib monotherapy (Cohort 1, N=23) during study follow-up. The confirmed objective response rates (ORR) in Cohort 1 and Cohort 2 were 60.9% and 90.5%, respectively, with a disease control rate (DCR) of 87% and 95.2%, respectively. Immature progression-free survival (“PFS”) data also showed a positive trend in favor of the combination therapy, with a median PFS of 9.3 months and 19.6 months in cohort 1 and cohort 2 with a maturity of 34.8% and 23.8%, respectively. Safety profiles of osimertinib monotherapy and osimertinib plus savolitinib were as expected, tolerable and manageable.